• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Phathom Pharmaceuticals Inc.

    3/12/26 4:46:41 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Phathom Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    03/06/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,178,411.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,178,411.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,178,411.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,178,411.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,178,411.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,178,411.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,178,411.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,178,411.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,178,411.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Phathom Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    100 Campus Drive, Suite 102, Florham Park, New Jersey 07932
    Item 2. 
    (a)Name of person filing:

    Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    71722W107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:03/11/2026
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:03/11/2026
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:03/11/2026
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of March 11, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $PHAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHAT

    DatePrice TargetRatingAnalyst
    3/27/2026$18.00Equal Weight → Overweight
    Barclays
    12/12/2025$28.00Strong Buy
    Raymond James
    12/9/2025$16.00Equal Weight
    Barclays
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    5/3/2024$24.00Buy
    Stifel
    1/5/2024$23.00 → $26.00Buy
    Needham
    8/9/2023$28.00Buy
    H.C. Wainwright
    5/11/2023In-line → Outperform
    Evercore ISI
    More analyst ratings

    $PHAT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parikh Asit received a gift of 28,000 shares and gifted 28,000 shares, decreasing direct ownership by 54% to 24,122 units (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/27/26 4:30:15 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Asit was granted 24,122 shares and exercised 17,500 shares at a strike of $4.95, increasing direct ownership by 396% to 52,122 units (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/21/26 5:16:32 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fields Heidi was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/21/26 4:30:10 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phathom Pharmaceuticals upgraded by Barclays with a new price target

    Barclays upgraded Phathom Pharmaceuticals from Equal Weight to Overweight and set a new price target of $18.00

    3/27/26 8:43:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Phathom Pharmaceuticals with a new price target

    Raymond James initiated coverage of Phathom Pharmaceuticals with a rating of Strong Buy and set a new price target of $28.00

    12/12/25 8:54:28 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Phathom Pharmaceuticals with a new price target

    Barclays initiated coverage of Phathom Pharmaceuticals with a rating of Equal Weight and set a new price target of $16.00

    12/9/25 8:52:32 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

    FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June: Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis, MNDate: Thursday, May 28, 2026 Management to participate in one-on-one meetings throughout the conference Jefferies Global Healthcare Conference in New York, NYDate: Wednesday, June 3, 2026Fireside Chat: 12:15 pm EDTManagement to participate in one-on-one

    5/22/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

    31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstractsIndependent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commer

    5/20/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

    FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois. Phathom will engage with the medical and scientific community through a series of activities, including a product theater presentation on VOQUEZNA® (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) approved for Gastroesophageal Reflux Disease (GERD), on Monday, May 4 at 12:00 PM CDT, along with a presence on the exhibi

    5/1/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAT
    SEC Filings

    View All

    SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

    8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

    5/21/26 4:01:07 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Phathom Pharmaceuticals Inc.

    10-Q - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

    4/30/26 7:05:35 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

    8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

    4/30/26 7:05:06 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Topper James N bought $14,609 worth of shares (3,780 units at $3.86) (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/23/25 4:06:35 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $24,462 worth of shares (7,420 units at $3.30) (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/15/25 4:17:38 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $152,917 worth of shares (48,203 units at $3.17) (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/13/25 4:13:04 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAT
    Leadership Updates

    Live Leadership Updates

    View All

    Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

    Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. "We welcome Sanjeev to Phathom's leadership team at this important stage of our growth," said Steve Basta, President

    10/6/25 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards. On June 23, 2025, the Compensation Committee of the Company's Board of Directors granted inducement awards to Ms. Cook under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Ms. Cook was granted a non-qualified stock option to purchase

    6/23/25 4:15:00 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se

    6/23/25 7:59:57 AM ET
    $PHAT
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAT
    Financials

    Live finance-specific insights

    View All

    Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

    ~1.35 million total VOQUEZNA® prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million, reflecting continued expense discipline and significant year-over-year cost reductionFY 2026 guidance maintained; operating profitability expected beginning in Q3 2026 and for FY 2026Conference call and webcast today, April 30, 2026, at 8:00 a.m. EDT FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointest

    4/30/26 6:59:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

    Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

    4/20/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

    FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion o

    2/17/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Phathom Pharmaceuticals Inc.

    SC 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    11/4/24 11:20:50 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Phathom Pharmaceuticals Inc.

    SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    8/22/24 4:05:55 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Phathom Pharmaceuticals Inc. (Amendment)

    SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    6/6/24 1:59:25 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care